You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

CLINICAL TRIALS PROFILE FOR GENTIAN VIOLET


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for gentian violet

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00128323 ↗ A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed British Society for Antimicrobial Chemotherapy Phase 3 2002-11-01 In resource constrained societies and where HIV is a problem, oral thrush causes significant morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin. GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark them out as having HIV infections. A much more dilute solution of GV has proved equally effective in vitro and would not carry the same cosmetic problem. In this study of children, the investigators have compared the 3 solutions, 1% GV, 0.00165% GV and nystatin oral drops - all masked so that they look the same - to see if GV is more effective than nystatin, and to see if the weaker solution of GV is as effective as the stronger solution.
NCT00128323 ↗ A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Completed University of Malawi College of Medicine Phase 3 2002-11-01 In resource constrained societies and where HIV is a problem, oral thrush causes significant morbidity. In adults, ketoconazole is used and sometimes oral nystatin. Both drugs are relatively expensive compared to GV solution and ketoconazole has significant side effects especially in association with some of the treatments for HIV related problems. In children, either GV solutions or nystatin are used, GV is a fraction of the cost of nystatin. GV at 1% solution discolours the mouth (blue) and in the older child and adult would mark them out as having HIV infections. A much more dilute solution of GV has proved equally effective in vitro and would not carry the same cosmetic problem. In this study of children, the investigators have compared the 3 solutions, 1% GV, 0.00165% GV and nystatin oral drops - all masked so that they look the same - to see if GV is more effective than nystatin, and to see if the weaker solution of GV is as effective as the stronger solution.
NCT00707174 ↗ Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna Completed University of Utah N/A 2005-03-01 This study is designed as a randomized, prospective study to test the efficacy of imiquimod plus tazarotene in the treatment of LM. Eligible and consented patients will be randomized to one of two treatment groups: 1) topical imiquimod group, or 2) topical imiquimod combined with topical tazarotene group. All patients will undergo a staged surgical excision with rush permanent sections to confirm negative histologic margins. This will be followed by a surgical repair of the defect and long-term follow-up of five years to rule out recurrences. Both groups will have a polygonal excision using 2mm margins per stage.
NCT01427738 ↗ Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 2011-06-01 The purpose of this study was to see which one of two medicines (topical gentian violet [GV] or nystatin oral suspension) was better than the other in treating Oral Candidiasis (OC). This was measured by whether the study participant still had OC or sores in his/her mouth after 14 days of treatment. Also, safety and tolerability of GV and nystatin in the treatment of OC were assessed.
NCT01427738 ↗ Gentian Violet Vs. Nystatin Oral Suspension for Treatment of Oropharyngeal Candidiasis Completed AIDS Clinical Trials Group Phase 3 2011-06-01 The purpose of this study was to see which one of two medicines (topical gentian violet [GV] or nystatin oral suspension) was better than the other in treating Oral Candidiasis (OC). This was measured by whether the study participant still had OC or sores in his/her mouth after 14 days of treatment. Also, safety and tolerability of GV and nystatin in the treatment of OC were assessed.
NCT01547221 ↗ Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients Completed Khon Kaen Hospital N/A 2012-03-01 Otomycosis is a superficial fungal infection of the external ear canal. Patients should be treated with cleaning fungal debris combined with topical antifungal agent. There is wide range of topical antifungal agents. However, there is still no consensus of the most effective topical antifungal agents in treatment otomycosis is still lacking. According to Thai National List of essential medicines for topical antifugal agents are: - acetic acid (2% in aqueous and 2% in 70% isopropyl alcohol) - boric acid (3% in isopropyl alcohol) - gentian violet - clotrimazole ear drop. But from literature review, there is no comparative study between boric acid and clotrimazole solution before. Objective is to compare the clinical effectiveness and adverse events of 1% clotrimazole solution versus 3% boric acid in 70% alcohol for the treatment of otomycosis.
NCT04388163 ↗ Gentian Violet Treatment for Hidradenitis Suppurativa Not yet recruiting Wake Forest University Health Sciences Phase 2 2021-11-01 This is a survey study being conducted to describe how subjects with Hidradenitis suppurativa (HS) respond to treatment with gentian violet. The study will rely primarily on qualitative survey responses and quantitative changes in skin appearance.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for gentian violet

Condition Name

Condition Name for gentian violet
Intervention Trials
Otomycosis 2
Cancer 1
Candidiasis, Oral 1
Hidradenitis Suppurativa 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for gentian violet
Intervention Trials
Candidiasis 2
Otomycosis 2
Lentigo 1
Hutchinson's Melanotic Freckle 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for gentian violet

Trials by Country

Trials by Country for gentian violet
Location Trials
United States 2
Malawi 2
South Africa 1
India 1
Kenya 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for gentian violet
Location Trials
North Carolina 1
Utah 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for gentian violet

Clinical Trial Phase

Clinical Trial Phase for gentian violet
Clinical Trial Phase Trials
Phase 3 2
Phase 2 1
N/A 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for gentian violet
Clinical Trial Phase Trials
Completed 4
Not yet recruiting 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for gentian violet

Sponsor Name

Sponsor Name for gentian violet
Sponsor Trials
Wake Forest University Health Sciences 1
Assiut University 1
British Society for Antimicrobial Chemotherapy 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for gentian violet
Sponsor Trials
Other 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.